Loading...
ABIVAX SA
ABVX.PA•EURONEXT
Healthcare
Biotechnology
€55.60
€-2.70(-4.63%)
ABIVAX SA (ABVX.PA) Financial Performance & Income Statement Overview
Review ABIVAX SA’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
0.00%
Net Income Growth
0.00%
Operating Cash Flow Growth
-58.62%
↓ 58.62%
Operating Margin
-1655.10%
↓ 1655.10%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-1633.08%
↓ 1633.08%
ROE
-211.00%
↓ 211.000%
ROIC
-160.59%
↓ 160.59%
ABIVAX SA (ABVX.PA) Income Statement & Financial Overview
Review ABIVAX SA's (ABVX.PA) income statement with detailed quarterly and annual figures.
| Metric | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|
| Revenue | $6.79M | $2.25M | $2.25M | $2.25M |
| Cost of Revenue | $0.00 | $378000.00 | $329000.00 | $32000.00 |
| Gross Profit | $6.79M | $1.87M | $1.92M | $2.22M |
| Gross Profit Ratio | $1.00 | $0.83 | $0.85 | $0.99 |
| R&D Expenses | $64.65M | $70.55M | $32.62M | $32.84M |
| SG&A Expenses | $22.16M | $21.91M | $6.58M | $5.15M |
| Operating Expenses | $86.78M | $95.59M | $39.21M | $37.99M |
| Total Costs & Expenses | $86.78M | $95.59M | $39.53M | $38.02M |
| Interest Income | $4.81M | $0.00 | $8.97M | $113000.00 |
| Interest Expense | $7.89M | $5.70M | $14.70M | $1.81M |
| Depreciation & Amortization | $171000.00 | $130000.00 | $329000.00 | $32000.00 |
| EBITDA | -$79.83M | -$90.05M | -$44.49M | -$40.71M |
| EBITDA Ratio | -$11.76 | -$40.11 | -$17.44 | -$16.90 |
| Operating Income | -$80.00M | -$90.18M | -$39.53M | -$38.02M |
| Operating Income Ratio | -$11.79 | -$40.17 | -$17.59 | -$16.91 |
| Other Income/Expenses (Net) | -$4.31M | -$7.95M | -$14.65M | -$4.53M |
| Income Before Tax | -$84.30M | -$95.79M | -$54.19M | -$42.55M |
| Income Before Tax Ratio | -$12.42 | -$42.67 | -$24.10 | -$18.93 |
| Income Tax Expense | -$2.67M | -$2.26M | -$2.23M | -$2.26M |
| Net Income | -$81.64M | -$95.79M | -$51.95M | -$40.29M |
| Net Income Ratio | -$12.03 | -$42.67 | -$23.11 | -$17.92 |
| EPS | -$1.30 | -$1.91 | -$1.45 | -$1.81 |
| Diluted EPS | -$1.30 | -$1.91 | -$1.45 | -$1.81 |
| Weighted Avg Shares Outstanding | $62.92M | $50.23M | $35.90M | $22.30M |
| Weighted Avg Shares Outstanding (Diluted) | $62.92M | $50.23M | $35.90M | $22.30M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan